Prediction of ADNI-mem, tau (flortaucipir) and Aβ (florbetapir) PET meta ROI SUVR tracer uptake for plasma p-Tau181 and plasma NfL baseline concentrations and rates of change over time (slope)
| Variable | Entire cohort (N=503) | A−TN− (N=192) | A+TN− (N=101) | A+TN+ (N=121) | A−TN+ (N=89) | |||||
| ADNI-mem | B (s.B) | p value | B (s.B) | P value | B (s.B) | P value | B (s.B) | P value | B (s.B) | P value |
| Plasma p-tau181 log10 baseline | −0.64 (-0.16) | <0.001 | −0.13 (-0.05) | 0.30 | −0.28 (-0.07) | 0.29 | −1.59 (-0.26) | <0.001 | −0.42 (-0.12) | 0.12 |
| Plasma NfL log10 baseline | −0.88 (-0.16) | <0.001 | −0.38 (-0.09) | 0.08 | −0.22 (-0.04) | 0.56 | −0.88 (-0.14) | 0.07 | −1.23 (-0.26) | <0.001 |
| Plasma p-tau181 slope | −2.49 (-0.02) | 0.38 | −3.47 (-0.05) | 0.23 | −5.39 (-0.05) | 0.40 | 0.82 (0.01) | 0.93 | −2.77 (-0.03) | 0.69 |
| Plasma NfL slope | −12.89 (-0.11) | <0.001 | −10.61 (-0.12) | 0.01 | −8.16 (-0.08) | 0.24 | −19.30 (-0.17) | 0.02 | 0.94 (0.01) | 0.91 |
| Tau PET | Entire cohort (N=196) | A−TN− (N=83) | A+TN− (N=40) | A+TN+ (N=41) | A−TN+ (N=32) | |||||
| Plasma p-tau181 log10 baseline | 0.68 (0.28) | <0.001 | 0.03 (0.05) | 0.68 | 0.15 (0.10) | 0.59 | 2.23 (0.35) | 0.03 | 0.24 (0.14) | 0.50 |
| Plasma NfL log10 baseline | 0.66 (0.18) | 0.02 | 0.08 (0.08) | 0.55 | −0.09 (-0.04) | 0.82 | 1.22 (0.18) | 0.29 | 0.07 (0.03) | 0.89 |
| Plasma p-tau181 slope | 2.92 (0.04) | 0.55 | 0.14 (0.01) | 0.93 | 10.04 (0.21) | 0.17 | 7.69 (0.05) | 0.77 | 2.46 (0.04) | 0.82 |
| Plasma NfL slope | 23.21 (0.27) | <0.001 | 0.83 (0.04) | 0.75 | 0.82 (0.25) | 0.12 | 49.20 (0.32) | 0.047 | 19.52 (0.31) | 0.097 |
| Amyloid PET | Entire cohort (N=103) | A−TN− (n=51) | A+TN− (n=19) | A+TN+ (n=16) | A−TN+ (N=17) | |||||
| Plasma p-tau181 log10 baseline | 0.76 (0.26) | 0.01 | −0.04 (-0.03) | 0.86 | 0.77 (0.18) | 0.52 | 0.56 (0.21) | 0.45 | 0.07 (0.04) | 0.88 |
| Plasma NfL log10 baseline | 1.08 (0.23) | 0.03 | 0.31 (0.14) | 0.81 | 0.53 (0.07) | 0.80 | 0.35 (0.10) | 0.70 | 0.10 (0.04) | 0.91 |
| Plasma p-tau181 slope | 5.88 (0.07) | 0.50 | 0.01 (0.12) | 0.44 | 57.49 (0.36) | 0.11 | −13.94 (-0.15) | 0.65 | −5.45 (-0.10) | 0.71 |
| Plasma NfL slope | 14.92 (0.14) | 0.16 | 8.76 (0.17) | 1.18 | 12.24 (0.09) | 0.69 | 10.04 (-0.13) | 0.62 | 19.69 (0.32) | 0.15 |
Analyses adjusted for age, sex and the time difference between baseline and ADNI-mem assessment/PET scan. Baseline cognition was included in the model when predicting ADNI-mem at follow-up.
Aβ, amyloid β; A+/−, Amyloid-β positive/negative; ADNI, Alzheimer’s Disease Neuroimaging Initiative; ATN, Aβ deposition, tau pathology and neurodegeneration; B, beta (slope); NfL, neurofilament light protein; p-tau181, plasma phosphorylated tau 181; s.B, standardised beta; TN+/−, Tau/Neurodegeneration positive/negative.